Topics

Olaparib Combo Shows Promise in Small Cell Lung Cancer

17:42 EDT 15 Aug 2019 | OncLive

Combining the PARP inhibitor olaparib (Lynparza) with temozolomide (Temodar) led to an overall response rate of 41.7% in patients with relapsed small cell lung cancer.

Original Article: Olaparib Combo Shows Promise in Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "Olaparib Combo Shows Promise in Small Cell Lung Cancer"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...